 John. R. Edwardson on Aug 17th, 2018 // No Comments
Wall Street analysts expect Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) to report earnings of ($0.28) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Aralez Pharmaceuticals' earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.32). Aralez Pharmaceuticals posted earnings of ($0.42) per share in the same quarter last year, which would suggest a positive year over year growth rate of 33.3%. The firm is expected to announce its next quarterly earnings report on Wednesday, August 22nd.
On average, analysts expect that Aralez Pharmaceuticals will report full-year earnings of ($0.78) per share for the current year, with EPS estimates ranging from ($0.84) to ($0.73). For the next fiscal year, analysts forecast that the company will report earnings of ($0.59) per share, with EPS estimates ranging from ($0.61) to ($0.56). Zacks' EPS calculations are an average based on a survey of analysts that that provide coverage for Aralez Pharmaceuticals. Get Aralez Pharmaceuticals alerts:
Separately, ValuEngine raised shares of Aralez Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Friday, June 1st. In other Aralez Pharmaceuticals news, insider Andrew I. Koven sold 156,573 shares of the company's stock in a transaction dated Monday, June 4th. The shares were sold at an average price of $0.37, for a total value of $57,932.01. Following the completion of the transaction, the insider now owns 1,183,419 shares in the company, valued at approximately $437,865.03. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website . 10.30% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARLZ. Wells Fargo & Company MN grew its position in Aralez Pharmaceuticals by 151.5% in the 4th quarter. Wells Fargo & Company MN now owns 686,931 shares of the company's stock worth $975,000 after purchasing an additional 413,801 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Aralez Pharmaceuticals by 159.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 261,606 shares of the company's stock worth $371,000 after purchasing an additional 160,621 shares during the last quarter. Finally, Salzhauer Michael grew its position in Aralez Pharmaceuticals by 107.1% in the 1st quarter. Salzhauer Michael now owns 220,153 shares of the company's stock worth $330,000 after purchasing an additional 113,860 shares during the last quarter. Hedge funds and other institutional investors own 14.71% of the company's stock.
Shares of NASDAQ:ARLZ opened at $0.05 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.80 and a debt-to-equity ratio of -41.79. Aralez Pharmaceuticals has a fifty-two week low of $0.04 and a fifty-two week high of $2.98. The stock has a market cap of $3.79 million, a P/E ratio of -0.04 and a beta of 1.20.
Aralez Pharmaceuticals Company Profile
Aralez Pharmaceuticals Inc operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial.
Get a free copy of the Zacks research report on Aralez Pharmaceuticals (ARLZ)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Aralez Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter 